Solara Active Pharma Converts 2.79 Lakh Rights Shares to Fully Paid-Up
Solara Active Pharma Sciences Limited converted 2,79,582 partly paid-up Rights Equity Shares into fully paid-up shares on August 19, 2026. This action follows the receipt of pending call monies and will result in necessary corporate actions for listing and trading approvals.
This is a procedural conversion of shares that were already part of a rights issue. It does not represent new fundraising or a significant change in the company's financial standing or operational outlook.
The announcement is a routine procedural update regarding the conversion of partly paid-up shares to fully paid-up shares after receiving call monies. It does not contain significant positive or negative financial news.
Solara Active Pharma Sciences Limited has announced the conversion of 2,79,582 partly paid-up Rights Equity Shares into fully paid-up equity shares. This decision was approved by the Rights Issue Committee of the Board of Directors via a circular resolution passed on August 19, 2026.
The conversion includes 2,23,051 Rights Equity Shares where the Second and Final Call monies were received, and 56,531 Rights Equity Shares where both the First Call Money and Second and Final Call monies were received. The company will undertake necessary steps for corporate actions and obtain listing and trading approvals for these converted shares.
Following this conversion, the company's paid-up capital stands at ₹48,16,16,569, comprising 4,80,81,817 fully paid-up equity shares, 59,419 partly paid-up equity shares (₹7 paid per share), and 1,09,276 partly paid-up equity shares (₹3.50 paid per share). This follows earlier intimations regarding the issuance of final reminder notices for pending call monies.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.